Recommendation of the President – Nucala (mepolizumab)
On 5 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 121/2024 on the appraisal of the drug Nucala (mepolizumab) under the drug program “Treatment of patients with active eosinophilic granulomatosis with vasculitis (EGPA) (ICD-10: M30.1)”